Celldex Historical Financial Ratios

CLDX Stock

USD 25.26 0.25 0.98%

Celldex Therapeutics is presently reporting on over 110 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 3.62 or Days Sales Outstanding of 132 will help investors to properly organize and evaluate Celldex Therapeutics financial condition quickly.

Quick Ratio Current Ratio

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Celldex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

For more information on how to buy Celldex Stock please use our How to Invest in Celldex Therapeutics guide.

About Celldex Financial Ratios Analysis

Celldex TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Celldex Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Celldex financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Celldex Therapeutics history.

Celldex Therapeutics Financial Ratios Chart

At this time, Celldex Therapeutics' Price To Sales Ratio is fairly stable compared to the past year. Days Sales Outstanding is likely to rise to 131.70 in 2025, whereas PTB Ratio is likely to drop 3.62 in 2025.

Price To Sales Ratio Days Sales Outstanding Average Payables Ev To Sales Current Ratio Price To Book Ratio

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Celldex Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Celldex Therapeutics sales, a figure that is much harder to manipulate than other Celldex Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Average Payables

The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Current Ratio

A liquidity ratio that measures a company's ability to pay short-term obligations or those due within one year. It compares a firm's current assets to its current liabilities.

Price To Book Ratio

A ratio used to compare a firm's market value to its book value, calculated by dividing the current closing price of the stock by the latest quarter's book value per share.

Most ratios from Celldex Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Celldex Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Celldex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

For more information on how to buy Celldex Stock please use our How to Invest in Celldex Therapeutics guide.At this time, Celldex Therapeutics' Price To Sales Ratio is fairly stable compared to the past year. Days Sales Outstanding is likely to rise to 131.70 in 2025, whereas PTB Ratio is likely to drop 3.62 in 2025.

	2022	2023	2024	2025 (projected)
Graham Number	20.25	24.12	27.74	26.35
Receivables Turnover	6.79	2.62	2.36	2.24

Graham Number Receivables Turnover

Celldex Therapeutics fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Average Payables	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow
Price To Sales Ratio		0.17	-0.14	-0.1	0.47	0.19	-0.16	0.53	0.17	1.0	0.19	0.27	0.08	0.03	-0.18	-0.56	0.64	0.23	-0.61	-0.2	-0.27	-0.61	0.67	-0.17	0.4	-0.63
Ptb Ratio	0.17		0.01	0.78	0.02	-0.91	0.69	-0.25	1.0	0.18	-0.91	0.34	-0.29	0.6	-0.73	-0.04	0.49	-0.28	-0.66	0.84	0.74	-0.67	0.18	0.91	-0.59	-0.65
Days Sales Outstanding	-0.14	0.01		-0.16	-0.34	-0.08	-0.17	0.06	0.01	-0.14	-0.08	-0.14	0.61	0.37	-0.47	0.17	-0.08	-0.39	0.07	0.25	0.15	0.07	0.33	0.1	-0.18	0.08
Book Value Per Share	-0.1	0.78	-0.16		-0.04	-0.81	0.68	-0.04	0.78	-0.11	-0.81	0.23	-0.51	0.14	-0.37	0.18	0.56	0.18	-0.39	0.6	0.48	-0.38	-0.18	0.77	-0.56	-0.35
Free Cash Flow Yield	0.47	0.02	-0.34	-0.04		0.25	-0.29	0.49	0.02	0.46	0.25	0.73	-0.09	-0.11	-0.01	-0.59	0.27	0.37	-0.45	-0.3	-0.37	-0.45	0.33	-0.25	0.71	-0.47
Operating Cash Flow Per Share	0.19	-0.91	-0.08	-0.81	0.25		-0.77	0.48	-0.91	0.18	1.0	-0.2	0.25	-0.62	0.67	-0.24	-0.26	0.42	0.38	-0.94	-0.87	0.38	0.05	-1.0	0.78	0.36
Average Payables	-0.16	0.69	-0.17	0.68	-0.29	-0.77		-0.46	0.69	-0.15	-0.77	0.08	-0.3	0.37	-0.3	0.34	0.25	-0.25	-0.22	0.69	0.62	-0.22	-0.41	0.77	-0.63	-0.19
Capex To Depreciation	0.53	-0.25	0.06	-0.04	0.49	0.48	-0.46		-0.25	0.51	0.48	0.22	0.14	-0.45	0.11	-0.46	0.62	0.77	-0.32	-0.58	-0.77	-0.3	0.35	-0.5	0.63	-0.31
Pb Ratio	0.17	1.0	0.01	0.78	0.02	-0.91	0.69	-0.25		0.18	-0.91	0.34	-0.29	0.6	-0.73	-0.04	0.49	-0.28	-0.66	0.84	0.74	-0.67	0.18	0.91	-0.59	-0.65
Ev To Sales	1.0	0.18	-0.14	-0.11	0.46	0.18	-0.15	0.51	0.18		0.18	0.26	0.09	0.05	-0.2	-0.56	0.63	0.2	-0.61	-0.18	-0.25	-0.61	0.67	-0.16	0.38	-0.63
Free Cash Flow Per Share	0.19	-0.91	-0.08	-0.81	0.25	1.0	-0.77	0.48	-0.91	0.18		-0.2	0.26	-0.62	0.66	-0.24	-0.26	0.42	0.38	-0.94	-0.87	0.38	0.05	-1.0	0.78	0.36
Roic	0.27	0.34	-0.14	0.23	0.73	-0.2	0.08	0.22	0.34	0.26	-0.2		0.05	0.42	-0.29	-0.42	0.33	0.0	-0.62	0.17	0.01	-0.62	0.29	0.23	0.44	-0.62
Inventory Turnover	0.08	-0.29	0.61	-0.51	-0.09	0.25	-0.3	0.14	-0.29	0.09	0.26	0.05		0.3	-0.3	0.0	-0.11	-0.38	0.07	0.01	-0.14	0.07	0.33	-0.21	0.25	0.05
Net Income Per Share	0.03	0.6	0.37	0.14	-0.11	-0.62	0.37	-0.45	0.6	0.05	-0.62	0.42	0.3		-0.72	-0.09	-0.01	-0.81	-0.48	0.74	0.68	-0.49	0.38	0.68	-0.33	-0.48
Days Of Inventory On Hand	-0.18	-0.73	-0.47	-0.37	-0.01	0.67	-0.3	0.11	-0.73	-0.2	0.66	-0.29	-0.3	-0.72		0.26	-0.32	0.49	0.52	-0.75	-0.63	0.53	-0.56	-0.69	0.42	0.52
Payables Turnover	-0.56	-0.04	0.17	0.18	-0.59	-0.24	0.34	-0.46	-0.04	-0.56	-0.24	-0.42	0.0	-0.09	0.26		-0.28	-0.2	0.55	0.27	0.27	0.55	-0.64	0.22	-0.48	0.57
Capex To Revenue	0.64	0.49	-0.08	0.56	0.27	-0.26	0.25	0.62	0.49	0.63	-0.26	0.33	-0.11	-0.01	-0.32	-0.28		0.47	-0.64	0.11	-0.14	-0.63	0.32	0.25	0.05	-0.62
Cash Per Share	0.23	-0.28	-0.39	0.18	0.37	0.42	-0.25	0.77	-0.28	0.2	0.42	0.0	-0.38	-0.81	0.49	-0.2	0.47		-0.03	-0.65	-0.72	-0.01	-0.16	-0.48	0.44	-0.02
Pocfratio	-0.61	-0.66	0.07	-0.39	-0.45	0.38	-0.22	-0.32	-0.66	-0.61	0.38	-0.62	0.07	-0.48	0.52	0.55	-0.64	-0.03		-0.31	-0.15	1.0	-0.49	-0.4	-0.09	1.0
Interest Coverage	-0.2	0.84	0.25	0.6	-0.3	-0.94	0.69	-0.58	0.84	-0.18	-0.94	0.17	0.01	0.74	-0.75	0.27	0.11	-0.65	-0.31		0.92	-0.32	0.02	0.96	-0.76	-0.3
Capex To Operating Cash Flow	-0.27	0.74	0.15	0.48	-0.37	-0.87	0.62	-0.77	0.74	-0.25	-0.87	0.01	-0.14	0.68	-0.63	0.27	-0.14	-0.72	-0.15	0.92		-0.16	0.01	0.88	-0.81	-0.14
Pfcf Ratio	-0.61	-0.67	0.07	-0.38	-0.45	0.38	-0.22	-0.3	-0.67	-0.61	0.38	-0.62	0.07	-0.49	0.53	0.55	-0.63	-0.01	1.0	-0.32	-0.16		-0.5	-0.41	-0.08	1.0
Days Payables Outstanding	0.67	0.18	0.33	-0.18	0.33	0.05	-0.41	0.35	0.18	0.67	0.05	0.29	0.33	0.38	-0.56	-0.64	0.32	-0.16	-0.49	0.02	0.01	-0.5		-0.01	0.22	-0.52
Income Quality	-0.17	0.91	0.1	0.77	-0.25	-1.0	0.77	-0.5	0.91	-0.16	-1.0	0.23	-0.21	0.68	-0.69	0.22	0.25	-0.48	-0.4	0.96	0.88	-0.41	-0.01		-0.76	-0.38
Roe	0.4	-0.59	-0.18	-0.56	0.71	0.78	-0.63	0.63	-0.59	0.38	0.78	0.44	0.25	-0.33	0.42	-0.48	0.05	0.44	-0.09	-0.76	-0.81	-0.08	0.22	-0.76		-0.11
Ev To Operating Cash Flow	-0.63	-0.65	0.08	-0.35	-0.47	0.36	-0.19	-0.31	-0.65	-0.63	0.36	-0.62	0.05	-0.48	0.52	0.57	-0.62	-0.02	1.0	-0.3	-0.14	1.0	-0.52	-0.38	-0.11

Click cells to compare fundamentals

Celldex Therapeutics Account Relationship Matchups

Celldex Therapeutics fundamentals Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Price To Sales Ratio	70.0	356.16	886.63	279.16	251.25	263.81
Ptb Ratio	2.48	3.95	6.41	4.48	4.03	3.62
Days Sales Outstanding	88.67	13.5	53.74	139.36	125.42	131.7
Book Value Per Share	7.06	9.78	6.96	8.86	10.19	9.68
Free Cash Flow Yield	(0.0808)	(0.0375)	(0.0505)	(0.0568)	(0.0653)	(0.0686)
Operating Cash Flow Per Share	(3.2)	(1.36)	(1.42)	(2.21)	(1.99)	(2.09)
Stock Based Compensation To Revenue	0.53	1.92	6.62	3.47	3.99	3.79
Capex To Depreciation	0.4	0.41	0.63	0.6	0.7	0.74
Pb Ratio	2.48	3.95	6.41	4.48	4.03	3.62
Ev To Sales	64.56	348.4	875.86	274.48	247.03	259.38
Free Cash Flow Per Share	(3.25)	(1.42)	(1.45)	(2.25)	(2.03)	(2.13)
Roic	(0.47)	(0.28)	(0.16)	(0.37)	(0.35)	(0.32)
Inventory Turnover	(42.04)	(23.6)	(17.84)	(4.03)	(4.64)	(4.87)
Net Income Per Share	(2.02)	(1.64)	(2.62)	(2.92)	(2.63)	(2.76)
Days Of Inventory On Hand	(8.68)	(15.46)	(20.46)	(90.47)	(104.04)	(98.84)
Payables Turnover	40.59	2.5	0.42	0.86	0.77	0.74
Sales General And Administrative To Revenue	1.95	4.41	11.54	4.49	5.17	4.91
Research And Ddevelopement To Revenue	5.73	11.46	34.9	17.15	15.43	16.2
Capex To Revenue	0.21	0.27	0.78	0.26	0.24	0.25
Cash Per Share	6.56	9.52	6.5	8.74	10.05	9.55
Pocfratio	(12.85)	(27.2)	(20.15)	(17.91)	(16.12)	(16.92)
Capex To Operating Cash Flow	(0.0384)	(0.0205)	(0.0176)	(0.0169)	(0.0153)	(0.016)
Pfcf Ratio	(12.38)	(26.65)	(19.8)	(17.61)	(15.85)	(16.64)
Days Payables Outstanding	8.99	146.1	870.79	423.97	487.57	883.16
Income Quality	0.5	0.91	0.68	0.92	0.76	0.44
Roe	(0.54)	(0.29)	(0.17)	(0.38)	(0.33)	(0.4)
Ev To Operating Cash Flow	(11.85)	(26.6)	(19.9)	(17.61)	(15.85)	(16.64)
Pe Ratio	(8.69)	(23.49)	(17.02)	(13.59)	(12.23)	(12.84)
Return On Tangible Assets	(0.3)	(0.17)	(0.38)	(0.32)	(0.37)	(0.39)
Ev To Free Cash Flow	(11.42)	(26.07)	(19.56)	(17.31)	(15.58)	(16.36)
Earnings Yield	(0.12)	(0.0426)	(0.0588)	(0.0736)	(0.0846)	(0.0889)
Intangibles To Total Assets	0.14	0.0681	0.0887	0.0584	0.0526	0.0499
Net Debt To E B I T D A	0.27	0.15	0.88	0.55	0.24	0.23
Current Ratio	13.93	24.86	17.07	13.87	12.48	13.11
Receivables Turnover	4.12	27.04	6.79	2.62	2.36	2.24
Graham Number	17.9	19.03	20.25	24.12	27.74	26.35
Shareholders Equity Per Share	7.06	9.78	6.96	8.86	10.19	9.68

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GM	General Motors
S	SentinelOne

Additional Tools for Celldex Stock Analysis

When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Celldex Historical Financial Ratios

About Celldex Financial Ratios Analysis

Celldex Therapeutics Financial Ratios Chart

Price To Sales Ratio

Average Payables

Ev To Sales

Current Ratio

Price To Book Ratio

Celldex Therapeutics fundamentals Correlations

Celldex Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Celldex Therapeutics fundamentals Accounts

Also Currently Popular

Additional Tools for Celldex Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ev To Sales	+ 1.0	Price To Sales Ratio
Pb Ratio	+ 1.0	Ptb Ratio
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Pfcf Ratio	+ 1.0	Pocfratio
Ev To Operating Cash Flow	+ 1.0	Pocfratio
Ev To Operating Cash Flow	+ 1.0	Pfcf Ratio

Income Quality	- 1.0	Free Cash Flow Per Share
Income Quality	- 1.0	Operating Cash Flow Per Share
Interest Coverage	- 0.94	Free Cash Flow Per Share
Interest Coverage	- 0.94	Operating Cash Flow Per Share
Free Cash Flow Per Share	- 0.91	Pb Ratio
Pb Ratio	- 0.91	Operating Cash Flow Per Share